An evergreen fund is focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Typical investment sizes range from $250K – $1M for early-stage companies. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments. The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. The firm is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. The firm is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital firm has offices in Northeastern US and Japan. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America. The firm may allocate up to $15 million per opportunity, but the amount initially committed varies dependent on the company’s stage of development, from under $1 million to $3-5 million for companies raising funds for IND-enabling studies.

The firm only invest in therapeutics, and are primarily focused on companies with preclinical assets. Within therapeutics, both small molecule and biologic opportunities are of interest. The firm may invest up to 18 months prior to IND, but require that a company has a lead asset that has been characterized, and has obtained proof of concept animal data that shows how the drug’s mechanism of action is playing out in the animal model. The firm also prefers that a company has additional follow-on drug candidates. In addition to preclinical opportunities, the firm also very selectively invests in companies with clinical-stage programs, but only in cases where the firm can add significant strategic value. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational computer giant aims to build a community of organizations who share a vision for shaping the future of their industry through the power of cognitive computing. The firm has set up a $100m equity investment fund with a mission to invest in strategic partnerships that exhibit the firm’s capabilities across industries. The firm makes business-led investment based on the application of firm’s core technology. The firm seeks minority participation in venture-led, Series A-C rounds and typically avoids seed stage investment. The firm is currently reviewing new opportunities from North America and Europe.

The firm empowers development of applications utilizing its core technology. Within healthcare, the firm is seeking B2B/B2B2C solutions in clinical care, home care, health management, biopharmaceutical R&D, and veterinary fields. Startups are selected based on business and technical synergy to become its partners, who will obtain access to its cloud service and enter strategic co-development partnership with the firm.

The firm is looking for top talent and industry expertise to accelerate awareness of cognitive applications. The firm does not require a board seat in its investee companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

One of the largest medical equipment companies in China is specialized in R&D, manufacturing and distribution of medical equipment. The firm is looking globally for collaboration, in-licensing, and M&A opportunities in medtech innovations that has a China angle. The firm typically seeks distribution rights in the Chinese market.

Within medtech, the firm is looking for technologies that can complement its existing product lines in respiratory system, circulatory system, endocrine system, home care, and hospital equipment. The firm has a special interest in disposable medical materials, digital devices, respiratory care equipment, and sleep monitoring technologies. The firm prefers class I and 510k devices that are within 1-2 years to FDA clearance.

The firm is seeking innovative technologies that can address unmet medical need in the Chinese market. The firm can utilize its manufacturing facilities to reduce production cost and leverage a marketing network and distribution channels of more than 150 service centers all over the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A South Korean pharmaceutical company that specializes in Gastrointestinal, CNS, and Metabolic products is actively searching for promising therapeutic candidates under development around the world to incorporate into its pipeline. The company is flexible in terms of the structure, but mostly in-licensing or co-development. The company is interested in world wide/major territories such as the US, EU, APAC, and East Asia.

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. The company is most interested in neurology, hepatology, and gastroenterology. However, the firm is also interested in other therapeutic areas that address large unmet medical needs. The company will look at both small molecules and biologics and will consider only NCE or NCE-like molecules (such as repositioning molecule, new indication, etc). The company prefers assets in phase I, II, or IND-ready. However, the company will also look at assets in phase III and NDA stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the Southern United States is currently seeking new investments in healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in the Southern U.S. but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, healthcare IT, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes.  The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm also willing to consider medical devices targeting these indication

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com